FI3774745T3 - Oksatsoliyhdistekide - Google Patents

Oksatsoliyhdistekide Download PDF

Info

Publication number
FI3774745T3
FI3774745T3 FIEP19718465.8T FI19718465T FI3774745T3 FI 3774745 T3 FI3774745 T3 FI 3774745T3 FI 19718465 T FI19718465 T FI 19718465T FI 3774745 T3 FI3774745 T3 FI 3774745T3
Authority
FI
Finland
Prior art keywords
crystal
infrared absorption
measured
peaks
rays
Prior art date
Application number
FIEP19718465.8T
Other languages
English (en)
Finnish (fi)
Inventor
Naohiko Kanai
Takayuki Yasutomi
Ryosuke Hirota
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of FI3774745T3 publication Critical patent/FI3774745T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
FIEP19718465.8T 2018-04-04 2019-04-03 Oksatsoliyhdistekide FI3774745T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018072717 2018-04-04
PCT/JP2019/014730 WO2019194211A1 (en) 2018-04-04 2019-04-03 Oxazole compound crystal

Publications (1)

Publication Number Publication Date
FI3774745T3 true FI3774745T3 (fi) 2024-06-19

Family

ID=66223774

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19718465.8T FI3774745T3 (fi) 2018-04-04 2019-04-03 Oksatsoliyhdistekide

Country Status (26)

Country Link
US (4) US11414391B2 (cg-RX-API-DMAC7.html)
EP (2) EP4400167A3 (cg-RX-API-DMAC7.html)
JP (4) JP7326295B2 (cg-RX-API-DMAC7.html)
KR (2) KR102764726B1 (cg-RX-API-DMAC7.html)
CN (1) CN111902402B (cg-RX-API-DMAC7.html)
AU (2) AU2019249562B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019377A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095866A1 (cg-RX-API-DMAC7.html)
DK (1) DK3774745T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092393A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982586T3 (cg-RX-API-DMAC7.html)
FI (1) FI3774745T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240858T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066793T2 (cg-RX-API-DMAC7.html)
IL (2) IL315425A (cg-RX-API-DMAC7.html)
LT (1) LT3774745T (cg-RX-API-DMAC7.html)
MX (1) MX2020010435A (cg-RX-API-DMAC7.html)
MY (1) MY202406A (cg-RX-API-DMAC7.html)
PH (1) PH12020551605A1 (cg-RX-API-DMAC7.html)
PL (1) PL3774745T3 (cg-RX-API-DMAC7.html)
PT (1) PT3774745T (cg-RX-API-DMAC7.html)
SG (1) SG11202009564TA (cg-RX-API-DMAC7.html)
SI (1) SI3774745T1 (cg-RX-API-DMAC7.html)
TW (2) TWI860993B (cg-RX-API-DMAC7.html)
WO (1) WO2019194211A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006134B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3774745T3 (pl) * 2018-04-04 2024-08-19 Otsuka Pharmaceutical Co., Ltd. Kryształ cząsteczki oksazolu
EP4501324A4 (en) 2022-03-25 2026-04-08 Otsuka Pharma Co Ltd WOUND TREATMENT COMPOSITION
CN115887463A (zh) * 2022-12-27 2023-04-04 瑞石生物医药有限公司 一种含环酰胺化合物的药物组合物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
US20260076788A1 (en) * 2024-09-17 2026-03-19 Natalie DeVoir Orthodontic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330639B (en) * 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
EP2890686B1 (en) * 2012-08-30 2017-01-04 Otsuka Pharmaceutical Co., Ltd. Method for producing oxazole compound
TWI726027B (zh) * 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 軟膏
PL3774745T3 (pl) * 2018-04-04 2024-08-19 Otsuka Pharmaceutical Co., Ltd. Kryształ cząsteczki oksazolu

Also Published As

Publication number Publication date
AU2019249562B2 (en) 2024-06-27
AU2024220015A1 (en) 2024-10-17
MX2020010435A (es) 2020-10-28
CA3095866A1 (en) 2019-10-10
IL277730B1 (en) 2024-10-01
IL315425A (en) 2024-11-01
JP2024001115A (ja) 2024-01-09
WO2019194211A1 (en) 2019-10-10
TW202012380A (zh) 2020-04-01
EP4400167A2 (en) 2024-07-17
US20250250243A1 (en) 2025-08-07
EP3774745B1 (en) 2024-05-29
EP3774745A1 (en) 2021-02-17
ZA202006134B (en) 2023-03-29
IL277730B2 (en) 2025-02-01
AU2019249562A1 (en) 2020-10-22
KR20250022254A (ko) 2025-02-14
US20210147370A1 (en) 2021-05-20
JP2021517111A (ja) 2021-07-15
PH12020551605A1 (en) 2021-04-26
TW202515853A (zh) 2025-04-16
JP7326295B2 (ja) 2023-08-15
LT3774745T (lt) 2024-07-10
CN111902402A (zh) 2020-11-06
JP2025128238A (ja) 2025-09-02
SI3774745T1 (sl) 2024-08-30
US20240076275A1 (en) 2024-03-07
IL277730A (en) 2020-11-30
JP2022037040A (ja) 2022-03-08
BR112020019377A2 (pt) 2021-01-05
CN111902402B (zh) 2026-07-14
SG11202009564TA (en) 2020-10-29
HRP20240858T1 (hr) 2024-10-11
PL3774745T3 (pl) 2024-08-19
ES2982586T3 (es) 2024-10-16
US11840512B2 (en) 2023-12-12
EP4400167A3 (en) 2024-09-25
US20220411386A1 (en) 2022-12-29
PT3774745T (pt) 2024-06-25
HUE066793T2 (hu) 2024-09-28
EA202092393A1 (ru) 2021-01-25
TWI860993B (zh) 2024-11-11
US11414391B2 (en) 2022-08-16
MY202406A (en) 2024-04-27
KR102764726B1 (ko) 2025-02-11
AU2024220015B2 (en) 2026-03-26
DK3774745T3 (da) 2024-06-17
KR20200139736A (ko) 2020-12-14

Similar Documents

Publication Publication Date Title
JP2016065042A5 (cg-RX-API-DMAC7.html)
MX373612B (es) Cristal del compuesto alquinil benceno 3,5-disustituido.
BR112022018600A2 (pt) Compostos, composição farmacêutica, método de tratamento de uma doença e combinação
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
HRP20240858T1 (hr) Kristal spoja oksazola
WO2015130842A3 (en) Ether compounds for treatment of complement mediated disorders
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
FI3977993T3 (fi) 6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä
EA200601273A1 (ru) Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат
RU2016137668A (ru) Новые производные каннабидиол-хинона
CY1110647T1 (el) Παραγωγα ν-(ετεροαρυλ)-1η-ινδολο-2-καρβοξαμιδιων και η χρηση τους ως δεσμοι του βανιλλοειδους υποδοχεα trpv1
WO2016164763A8 (en) Compositions and methods for treating cns disorders
WO2014136282A8 (en) Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
WO2024006726A3 (en) Compounds as inhibitors of axl
JP2022037040A5 (cg-RX-API-DMAC7.html)
Prasad et al. Effect of inductive effect on the formation of cocrystals and eutectics
WO2018083635A3 (en) Tricyclic heterocyclic derivatives and uses thereof
JP2021517111A5 (cg-RX-API-DMAC7.html)
WO2015042414A8 (en) Multicyclic compounds and methods of using same
WO2014164648A4 (en) Solid state forms of a quinazoline derivative and its use as a braf inhibitor
WO2019207257A8 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
PH12019502588A1 (en) Crystal form c of sanzuohuangcaotong, preparation method and use thereof
WO2020132471A8 (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
MY202100A (en) Crystal